Efficacy of Taxotere, Thalidomide, and Prednisolone in Patients with Hormone-Resistant Metastatic Prostate Cancer

被引：2
|
作者：
Rezvani, Hamid [1 ]
Ghadyani, Shirin Haghighi Mojtaba [1 ]
Attarian, Hamid [1 ]
机构：
[1] Shahid Beheshti Univ Med Sci, Taleghani Hosp, Tehran, Iran
来源：
UROLOGY JOURNAL | 2012年 / 9卷 / 04期
关键词：
prostatic neoplasms; treatment failure; antineoplastic agents; drug resistance; PHASE-II TRIAL; MITOXANTRONE PLUS PREDNISONE; CLINICAL-TRIALS; WORKING GROUP; DOCETAXEL; ANGIOGENESIS; RECOMMENDATIONS; GUIDELINES; INHIBITOR; REGISTRY;
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
Purpose: To evaluate the efficacy and safety of combination treatment with thalidomide and taxotere in patients with hormone-resistant prostate cancer. Materials and Methods: This clinical trial was performed on 16 patients with hormone-resistant prostate cancer. Results: Mean age of the participants was 72.7 +/- 5.39 years (range, 65 to 85 years). In 94% of patients who received the drug combination, prostate-specific antigen level decreased more than 50%. The mean time to progression was 15 months and mean survival time was 23 months. This combination therapy had some adverse events. Conclusion: Addition of anti-angiogenic agents, such as thalidomide, can improve therapeutic outcome in this group of patients.
引用
收藏
页码：673 / 677
页数：5
相关论文
共 50 条
  • [41] Role of DNA methyltransferase 1 in hormone-resistant prostate cancer
    Miao-Fen Chen
    Wen-Cheng Chen
    Yu-Jia Chang
    Ching-Fang Wu
    Chun-Te Wu
    Journal of Molecular Medicine, 2010, 88 : 953 - 962
  • [42] CYTOTOXIC CHEMOTHERAPY FOR ADVANCED HORMONE-RESISTANT PROSTATE-CANCER
    YAGODA, A
    PETRYLAK, D
    CANCER, 1993, 71 (03) : 1098 - 1109
  • [43] MitoxantroneA Review of its Pharmacology and Clinical Efficacy in the Management of Hormone-Resistant Advanced Prostate Cancer
    Lynda R. Wiseman
    Caroline M. Spencer
    Drugs & Aging, 1997, 10 : 473 - 485
  • [44] Gene amplifications associated with the development of hormone-resistant prostate cancer
    Edwards, J
    Krishna, S
    Witton, CJ
    Bartlett, JMS
    CLINICAL CANCER RESEARCH, 2003, 9 (14) : 5271 - 5281
  • [45] A phase II study of tamoxifen in hormone-resistant metastatic prostate cancer: Possible relation with prolactin secretion
    Lissoni, P
    Vigano, P
    Vaghi, M
    Frontini, L
    Giuberti, C
    Manganini, V
    Casu, M
    Brivio, F
    Niespolo, R
    Strada, G
    ANTICANCER RESEARCH, 2005, 25 (05) : 3597 - 3599
  • [46] CHEMOTHERAPY IN ELDERLY PATIENTS WITH HORMONE RESISTANT METASTATIC PROSTATE CANCER
    Costa, A. S.
    Meireles, S.
    Almeida, D.
    Salgado, M.
    Aguas, L.
    Davila, C.
    Rey, C.
    Caeiro, C.
    Augusto, I.
    Damasceno, M.
    ANNALS OF ONCOLOGY, 2010, 21 : 302 - 303
  • [47] Vandetanib for treatment of hormone-resistant prostate cancer and docetaxel-resistant prostate cancer. Preclinical study
    Guerin, O.
    Etienne-Grimaldi, M.
    Fischel, J.
    Formento, P.
    Milano, G.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2011, 25 : 5 - 5
  • [48] UK STUDIES ON SURAMIN THERAPY IN HORMONE-RESISTANT PROSTATE-CANCER
    KEHINDE, EO
    TERRY, TR
    MISTRY, N
    HORSBURGH, T
    SANDHU, DP
    BELL, PRF
    CANCER SURVEYS, 1995, 23 : 217 - 229
  • [49] Circulating tumor cells as a potential efficacy end point in clinical trials of hormone-resistant prostate cancer
    Samir S. Taneja
    Current Urology Reports, 2009, 10 (1) : 4 - 5
  • [50] Inelcalcitol targets vitamin D receptors in hormone-resistant prostate cancer
    不详
    FUTURE MEDICINAL CHEMISTRY, 2011, 3 (01) : 6 - 6
12345